-
In a family-based research cohort, men were followed for up to 40 years after the birth of their children, and those with only daughters had a 40% higher risk of prostate cancer compared with men with at least one son.
-
Trastuzumab has previously been demonstrated to be active against HER2 positive breast cancer when used in the metastatic setting.
-
Imatinib inhibits the BCR/ABL tyrosine kinase in CML, leading to improved responses over standard therapy. This report provides 5 year follow-up from the seminal IRIS study of upfront imatinib for chronic phase CML among the 553 patients randomized to 400 mg of imatinib.
-
Patients with coronary artery disease who have received intra-coronary, drug-eluding stents (DES) may benefit from longer courses of clopidogrel than is currently standard.
-
An increasing number of active therapies have become available for multiple myeloma in addition to high dose chemotherapy followed by autologous transplant (ASCT).
-
Breast cancer patients who received either high-dose, standard-dose or no chemotherapy were studied prospectively, utilizing a comprehensive battery of neuropsych tests.
-
Immediate breast reconstruction after mastectomy has intuitive appeal, but concern has been raised that such an approach hinders postmastectomy radiotherapy.
-
-
Optimal treatment for carcinoma of unknown primary has not been established. In a multicenter, randomized Phase II trial, 66 patients were treated with cisplatin, gemcitabine and either paclitaxel or vinorelbine.
-
In 47 patients with newly diagnosed colorectal cancer, staging by combined CT and PET was compared to CT followed at a later time by PET or by CT alone.
